BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)
Close on Nov 17, 2026Market cap $2.25MP/E –Yield –
BioNexus Gene Lab gross margin
Gross margin is gross profit as a percentage of revenue.
BioNexus Gene Lab's gross margin for the twelve months ending Jun 30, 2026 was 12.3%. For fiscal 2025 it was 14.6%, against 13.6% the year before. The highest annual figure on record is 44.0% in fiscal 2019.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 14.6% | +1.1 |
| FY2024 | Dec 31, 2024 | 13.6% | −0.0 |
| FY2023 | Dec 31, 2023 | 13.6% | +2.1 |
| FY2022 | Dec 31, 2022 | 11.5% | −5.4 |
| FY2021 | Dec 31, 2021 | 17.0% | +1.9 |
| FY2020 | Dec 31, 2020 | 15.1% | −28.9 |
| FY2019 | Dec 31, 2019 | 44.0% | +30.5 |
| FY2018 | Dec 31, 2018 | 13.5% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 17.0% | +0.8 |
| Q1 FY2026 | Mar 31, 2026 | -3.5% | −19.5 |
| Q4 FY2025 | Dec 31, 2025 | -0.8% | −13.1 |
| Q3 FY2025 | Sep 30, 2025 | 14.8% | +2.4 |
| Q2 FY2025 | Jun 30, 2025 | 16.3% | +1.7 |
| Q1 FY2025 | Mar 31, 2025 | 16.1% | +0.7 |
| Q4 FY2024 | Dec 31, 2024 | 12.3% | +0.5 |
| Q3 FY2024 | Sep 30, 2024 | 12.4% | −1.5 |
| Q2 FY2024 | Jun 30, 2024 | 14.6% | +1.4 |
| Q1 FY2024 | Mar 31, 2024 | 15.3% | −0.2 |
| Q4 FY2023 | Dec 31, 2023 | 11.7% | −0.2 |
| Q3 FY2023 | Sep 30, 2023 | 13.9% | +2.2 |
| Q2 FY2023 | Jun 30, 2023 | 13.2% | +2.6 |
| Q1 FY2023 | Mar 31, 2023 | 15.5% | +3.8 |
| Q4 FY2022 | Dec 31, 2022 | 11.9% | −2.8 |
| Q3 FY2022 | Sep 30, 2022 | 11.6% | −8.2 |
| Q2 FY2022 | Jun 30, 2022 | 10.6% | −4.5 |
| Q1 FY2022 | Mar 31, 2022 | 11.8% | −5.1 |
| Q4 FY2021 | Dec 31, 2021 | 14.7% | +5.4 |
| Q3 FY2021 | Sep 30, 2021 | 19.8% | +2.9 |
| Q2 FY2021 | Jun 30, 2021 | 15.1% | +0.7 |
| Q1 FY2021 | Mar 31, 2021 | 16.9% | −4.5 |
| Q4 FY2020 | Dec 31, 2020 | 9.3% | −55.4 |
| Q3 FY2020 | Sep 30, 2020 | 16.9% | −14.9 |
| Q2 FY2020 | Jun 30, 2020 | 14.4% | −6.9 |
| Q1 FY2020 | Mar 31, 2020 | 21.3% | −11.6 |
| Q4 FY2019 | Dec 31, 2019 | 64.7% | +136.2 |
| Q3 FY2019 | Sep 30, 2019 | 31.7% | +7.3 |
| Q2 FY2019 | Jun 30, 2019 | 21.4% | −1.7 |
| Q1 FY2019 | Mar 31, 2019 | 33.0% | – |
| Q4 FY2018 | Dec 31, 2018 | -71.5% | – |
| Q3 FY2018 | Sep 30, 2018 | 24.4% | – |
| Q2 FY2018 | Jun 30, 2018 | 23.0% | – |
See a number that looks wrong?